相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
Nina D. Wagner-Johnston et al.
CANCER (2015)
Denosumab: A novel antiresorptive drug for osteoporosis
Ernest Suresh et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2015)
Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program
Alexandra Papaioannou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study
P. Hadji et al.
OSTEOPOROSIS INTERNATIONAL (2015)
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
S. Papapoulos et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
S. Ferrari et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial
S. L. Greenspan et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
L. Karlsson et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases
M. O'Halloran et al.
AUSTRALIAN DENTAL JOURNAL (2014)
A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture
Helena Johansson et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL DENSITOMETRY (2014)
Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials
JoAnn E. Manson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Treat-to-target for Osteoporosis: Is Now the Time?
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial
Andrew Grey et al.
BONE (2012)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Five Years of Continued Therapy in a Phase 2 Study
Bente Langdahl et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2012)
The relationship of denosumab pharmacology and osteonecrosis of the jaws
John Malan et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2012)
Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation
Philipp Diehl et al.
CLINICAL RESEARCH IN CARDIOLOGY (2011)
Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy A Randomized Controlled Trial
Andrea Z. LaCroix et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization
Roksana Karim et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2011)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
Michael McClung et al.
OBSTETRICS AND GYNECOLOGY (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin
Gerardo Heiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women
E Banks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography
TE Dufresne et al.
CALCIFIED TISSUE INTERNATIONAL (2003)
Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial
JA Cauley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy -: A randomized controlled trial
BH Ascott-Evans et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers
JC Gallagher et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women
SJM Neele et al.
BONE (2002)
Bone mass response to of long-term hormone discontinuation replacement therapy - Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study
GA Greendale et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
分享论文
